Abstract
Demographers were among the first to emphasize the importance of age in explaining the spread and impact on mortality of COVID-19. Yet, the relationship between age and COVID-19 is not fully understood. This study aims to answer the following questions: Do COVID-19 deaths follow the Gompertz force of mortality? How does the relationship between age and COVID-19 mortality compare with other major causes of death? Does this relationship vary between countries? Using US vital Statistics, COVID-19 mortality doubling time is compared with 68 major cause of death categories. COVID-19 fatality is similarly compared across 33 countries using COVerAGE-DB, a harmonized dataset of confirmed COVID-19 cases and deaths. Several findings are supported by the evidence. First, COVID-19 mortality increasing exponentially with age at a rate near the median of aging-related causes of death, as well as pneumonia and influenza. Second, COVID-19 mortality levels in the US are currently 4 to 8 times higher than pneumonia and influenza across the adult age range. Third, the relationship between COVID-19 fatality and age varies considerably across high-income countries. Fourth, these regularities can be utilized for indirect estimation of COVID-19 deaths by age. In conclusion, the relationship between COVID-19 mortality and age resembles the population rate of aging. Between-country variation in the Gompertz slope of COVID-19 fatality may point to differences in underlying population health, standards of clinical care, and data quality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The analysis is based on aggregate, publicly available data, and does not require IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
isasson{at}tauex.tau.ac.il
